341 related articles for article (PubMed ID: 35165339)
1. Dual-sgRNA CRISPR/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization.
Fierro J; DiPasquale J; Perez J; Chin B; Chokpapone Y; Tran AM; Holden A; Factoriza C; Sivagnanakumar N; Aguilar R; Mazal S; Lopez M; Dou H
Sci Rep; 2022 Feb; 12(1):2417. PubMed ID: 35165339
[TBL] [Abstract][Full Text] [Related]
2. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.
Yahata T; Mizoguchi M; Kimura A; Orimo T; Toujima S; Kuninaka Y; Nosaka M; Ishida Y; Sasaki I; Fukuda-Ohta Y; Hemmi H; Iwahashi N; Noguchi T; Kaisho T; Kondo T; Ino K
Cancer Sci; 2019 Apr; 110(4):1279-1292. PubMed ID: 30702189
[TBL] [Abstract][Full Text] [Related]
3. Using a Dual CRISPR/Cas9 Approach to Gain Insight into the Role of LRP1B in Glioblastoma.
Peixoto J; Príncipe C; Pestana A; Osório H; Pinto MT; Prazeres H; Soares P; Lima RT
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511044
[No Abstract] [Full Text] [Related]
4. sgRNA Sequence Motifs Blocking Efficient CRISPR/Cas9-Mediated Gene Editing.
Graf R; Li X; Chu VT; Rajewsky K
Cell Rep; 2019 Jan; 26(5):1098-1103.e3. PubMed ID: 30699341
[TBL] [Abstract][Full Text] [Related]
5. Optimized CRISPR/Cas9 system for gene knockout in chicken DF1 cells.
Zou K; Wang F; Zhang Z; Zhou Y; Li P; Wang D; Zhu M; Jia C; Wei Z
Poult Sci; 2023 Oct; 102(10):102970. PubMed ID: 37562129
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of lipid Nanoparticle-Mediated delivery of CRISPR-Cas9 RNP versus mRNA/sgRNA for gene editing in vitro and in vivo.
Walther J; Porenta D; Wilbie D; Seinen C; Benne N; Yang Q; de Jong OG; Lei Z; Mastrobattista E
Eur J Pharm Biopharm; 2024 Mar; 196():114207. PubMed ID: 38325664
[TBL] [Abstract][Full Text] [Related]
7. Targeting RLIP with CRISPR/Cas9 controls tumor growth.
Singhal J; Chikara S; Horne D; Awasthi S; Salgia R; Singhal SS
Carcinogenesis; 2021 Feb; 42(1):48-57. PubMed ID: 32426802
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation.
Qiu XY; Hu DX; Chen WQ; Chen RQ; Qian SR; Li CY; Li YJ; Xiong XX; Liu D; Pan F; Yu SB; Chen XQ
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1754-1769. PubMed ID: 29510196
[TBL] [Abstract][Full Text] [Related]
9. [ADRB2 Gene Knockout in Human Primary T Cells by Multiple sgRNAs Construced using CRISPR/Cas9 Technology].
Sun Y; Liu D; Shi M; Zheng JN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1682-1690. PubMed ID: 31607332
[TBL] [Abstract][Full Text] [Related]
10. Optimized Cas9:sgRNA delivery efficiently generates biallelic MSTN knockout sheep without affecting meat quality.
Zhou S; Kalds P; Luo Q; Sun K; Zhao X; Gao Y; Cai B; Huang S; Kou Q; Petersen B; Chen Y; Ma B; Wang X
BMC Genomics; 2022 May; 23(1):348. PubMed ID: 35524183
[TBL] [Abstract][Full Text] [Related]
11. Applications of CRISPR-Cas9 Technology to Genome Editing in Glioblastoma Multiforme.
Al-Sammarraie N; Ray SK
Cells; 2021 Sep; 10(9):. PubMed ID: 34571991
[TBL] [Abstract][Full Text] [Related]
12. Synergistic Antitumor Effect on Bladder Cancer by Rational Combination of Programmed Cell Death 1 Blockade and CRISPR-Cas9-Mediated Long Non-Coding RNA Urothelial Carcinoma Associated 1 Knockout.
Zhen S; Lu J; Chen W; Zhao L; Li X
Hum Gene Ther; 2018 Dec; 29(12):1352-1363. PubMed ID: 30457360
[TBL] [Abstract][Full Text] [Related]
13. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H
Cells; 2020 Apr; 9(4):. PubMed ID: 32316275
[TBL] [Abstract][Full Text] [Related]
14. Construction of Traf3 knockout liver cancer cell line using CRISPR/Cas9 system.
Hu W; Guo G; Chi Y; Li F
J Cell Biochem; 2019 Sep; 120(9):14908-14915. PubMed ID: 31016787
[TBL] [Abstract][Full Text] [Related]
15. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
16. Selection of highly efficient sgRNAs for CRISPR/Cas9-based plant genome editing.
Liang G; Zhang H; Lou D; Yu D
Sci Rep; 2016 Feb; 6():21451. PubMed ID: 26891616
[TBL] [Abstract][Full Text] [Related]
17. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
18. Construction of an Inducible CRISPR/Cas9 System for CXCR4 Gene and Demonstration of its Effects on MKN-45 Cells.
Peng Y; Yang T; Tang X; Chen F; Wang S
Cell Biochem Biophys; 2020 Mar; 78(1):23-30. PubMed ID: 31875277
[TBL] [Abstract][Full Text] [Related]
19. Design Principles of a Novel Construct for HBB Gene-Editing and Investigation of Its Gene-Targeting Efficiency in HEK293 Cells.
Lotfi M; Ashouri A; Mojarrad M; Mozaffari-Jovin S; Abbaszadegan MR
Mol Biotechnol; 2024 Mar; 66(3):517-530. PubMed ID: 37266832
[TBL] [Abstract][Full Text] [Related]
20. Activation of the cGAS-STING pathway combined with CRISPR-Cas9 gene editing triggering long-term immunotherapy.
Lu Q; Chen R; Du S; Chen C; Pan Y; Luan X; Yang J; Zeng F; He B; Han X; Song Y
Biomaterials; 2022 Dec; 291():121871. PubMed ID: 36323073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
